Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo approach may spare sinus cancer patients from major surgery

NCT ID NCT07320508

Disease control Sponsor: Eye & ENT Hospital of Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with a rare sinus cancer called sinonasal adenoid cystic carcinoma. The treatment delivers high-dose chemotherapy directly to the tumor through a small tube in an artery, aiming to shrink it as much as possible. After three sessions, doctors check if the tumor is gone; if so, patients get only radiation, avoiding major surgery. The goal is to see if this personalized approach is safe and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 70 years. 2. Histologically confirmed diagnosis of sinonasal adenoid cystic carcinoma (ACC). 3. Tumor stage T3 or T4 according to the AJCC (American Joint Committee on Cancer) 8th edition staging system. Participants with lymph node metastasis must be amenable to surgical dissection. Those with distant metastasis must have stable disease. 4. Ability to provide a sufficient volume (≥0.5 cm³) of fresh tumor tissue via biopsy or surgery for research purposes, with participant's informed consent. 5. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 to 2. 6. Voluntary participation and provision of written informed consent. Good compliance, able to cooperate with treatment and follow-up. Exclusion Criteria: 1. Prior treatment with Epirubicin or any other anthracycline-based chemotherapy. 2. Prior radiotherapy to the head and neck region. 3. Administration of any other chemotherapy, targeted therapy, or immunotherapy within 4 weeks prior to study enrollment. 4. Concurrent participation in another interventional drug clinical trial. 5. Inadequate liver, kidney, or bone marrow function that does not meet the requirements for the planned treatment regimen. 6. Contraindications to anthracycline-containing chemotherapy regimens: known allergy to anthracyclines, presence of ≥ Grade 2 peripheral neuropathy, or uncontrolled nausea/vomiting or chronic gastrointestinal diseases. 7. Severe uncontrolled acute infection or decompensated major organ dysfunction. 8. Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenoid cystic carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma nasal cavity and paranasal sinus carcinoma paranasal sinus adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenoid cystic carcinoma Epirubicin Sinonasal carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eye and ENT Hospital, Fudan University

    RECRUITING

    Shanghai, Xuhui Strict, 200031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.